Results 11 to 20 of about 22,513 (247)
Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy
Hepatology, EarlyView., 2022 Abstract Background and Aims Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural ...
Nadja Meumann +25 more
wiley +1 more source
Postgraduate Medical Journal, 1997 Summary Although the nature of haemophilia has been understood for thousands of years, knowledge of its molecular genetics is recent. These X-linked bleeding disorders have diverse underlying DNA defects and, in 1992, DNA inversion within the X chromosome was found to explain half of the most serious cases of haemophilia A. The life-span
Cahill, Mary R., Colvin, B. T.
openaire +3 more sources
Journal of Ayub Medical College Abbottabad, 2023 Acquired haemophilia A (AHA) is a rare disease believed to be caused by spontaneous inhibition of clotting Factor VIII by autoantibodies. This is in contrast to the more common congenital haemophilias which are largely due to an absolute deficiency in coagulation factors. It has a prevalence of approximately one per million per year.
Ewe Jin Koh +5 more
openaire +2 more sources
Factor VIII products: key aspects of development, clinical research and use (part 2)
Биопрепараты: Профилактика, диагностика, лечение, 2021 Continuous replacement therapy with clotting factor products can lead to serious complications in haemophilia A patients. One of potential reasons of such complications is an undesirable immune response to a blood clotting factor VIII (FVIII) product ...
Zh. I. Avdeeva +4 more
doaj +1 more source
Hematology, 2023 Background and Objectives Haemophilia comprises a continuum of blood disorders that often include joint and muscular dysfunction, which may lead to a constellation of activity limitations and participation restrictions.
Bao-Feng Geng +4 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2019 Background Thrombin generation assay (TGA) and thrombelastography (TEG) are increasingly employed, global, in vitro methods for assessment of the procoagulant potential of plasma/blood and possibly ideally suited tools to monitor, for example, therapy ...
Egon Persson, Mette Winther
doaj +1 more source
Acquired haemophilia A: a case report
Studia Medyczne, 2017 Acquired haemophilia A is rare, autoimmune bleeding disorder caused by the production of autoantibodies against coagulation factor VIII (FVIII). The disorder affects 1.5 people per 1 million population a year, particularly the elderly.
Adam Stemplewski +3 more
doaj +1 more source
Endodontic Management of a Haemophilic Patient- A Clinical Perspective [PDF]
Journal of Clinical and Diagnostic Research, 2014 Haemophilia and other bleeding disorders remain an enigma to the dentists world over. They not only challenge the skills of dental specialists but also raise the question of how these individuals should be managed emotionally as well as psychologically.
Pooja Gupta Dudeja +3 more
doaj +1 more source
Three-Decade Successive Establishment of Care for Women/Girls from Families with Haemophilia
The Application of Clinical Genetics, 2022 Ampaiwan Chuansumrit,1 Werasak Sasanakul,1 Nongnuch Sirachainan,1 Suttikarn Santiwatana,1 Praguywan Kadegasem,1 Pakawan Wongwerawattanakoon,2 Noppawan Tungbubpha,1 Juthamard Chantaraamporn1 1Department of Pediatrics, Faculty of Medicine, Ramathibodi ...
Chuansumrit A +7 more
doaj
Haematology Journal of Bangladesh, 2021 Haemophilia is one of the most common bleeding disorders globally. Though the prevalence of haemophilia in Bangladesh according to the ‘World Haemophilia Registry’ is ten per million people, the original prevalence would be much higher. There is lack of
M Morsed Zaman Miah +2 more
doaj +1 more source